TORONTO, Oct. 16, 2023 /CNW/ - Newtopia Inc. ("Newtopia" or the "Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow, and reverse chronic disease, is pleased to announce that it closed the second [and final] tranche of its previously announced non-brokered offering of subordinated and postponed 12% secured non-convertible debenture units (the "Units") for gross proceeds of CAD$425,000 (the "Offering").
Each Unit is comprised of: (i) $10,000 principal amount of subordinated and postponed secured non-convertible debentures of the Company (the "Debentures"); and (ii) for no additional consideration, 8,695 common shares of the Company (each whole common share, a "Bonus Share", and collectively, the "Bonus Shares"). The Bonus Shares are calculated based on 10% of the principal amount of the Debentures purchased divided by $0.115, being the closing market price of the common shares of the Company on September 11, 2023, being the closing price on the trading day prior to the day on which the Offering was initially announced. The securities issued pursuant to the Offering are subject to a four month hold period that expires on February 14, 2024. An aggregate of 369,562 Bonus Shares were issued in connection with the closing of this second tranche of the Offering.
The Debentures issued in connection with this second tranche of the Offering will mature on October 13, 2024 (the "Maturity Date") and are secured by the assets of the Company and bear interest at a rate of 12.0% per annum payable quarterly in arrears in cash.
The Company will pay to the holders of the Debentures a work and credit maintenance fee of 2% of the principal amount in cash payable 60 days following the closing date of the Offering (the "Closing Date").
The Debentures may be repaid in part or in full at any time subject to an early repayment fee equal to: (i) 6% of the principal amount of the Debentures if repayment occurs prior to the date that is six months following the Closing Date; or (ii) 4% of such principal amount if repayment occurs following the date that is six months following the Closing Date but prior to the Maturity Date.
The Debentures, the Bonus Shares and the Compensation Options (as defined below) issued pursuant to the Offering will be subject to a hold period of four months plus one day from the Closing Date, except as permitted by applicable securities legislation and the rules of the TSX Venture Exchange (the "Exchange"). The Offering is subject to final approval by the Exchange.
Certain finders acting in connection with the Offering received a finder's fee in the aggregate total amount of $1,800 and 15,652 non-transferable compensation options (the "Compensation Option"). The Compensation Options were calculated based on 6% of the principal amount of Debentures purchased by subscribers that were introduced to the Company by each such finder divided by $0.115, being the closing market price of the common shares of the Company on the Exchange on September 11, 2023. Each Compensation Option is exercisable into one common share of the Company at $0.115 per share, subject to adjustments in certain events, until October 13, 2025.
As previously announced, the Company will use the proceeds of the Offering to repay certain debentures that matured on October 15, 2023.
Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse chronic disease while reducing healthcare costs. The platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed in Canada on the Toronto Stock Exchange (TSXV: NEWU) and is quoted in the US on the OTCQB® Venture Market (OTCQB: NEWUF). To learn more, visit newtopia.com , LinkedIn or Twitter.
This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable United States securities legislation (collectively, "forward-looking statements"), which reflects management's expectations regarding Newtopia's future growth, results from operations (including, without limitation, future production and capital expenditures), performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as "predicts", "projects", "targets", "plans", "expects", "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Newtopia's current views and intentions with respect to future events, based on information available to Newtopia, and are subject to certain risks, uncertainties, and assumptions. Material factors or assumptions were applied in providing forward-looking information. While forward-looking statements are based on data, assumptions and analyses that Newtopia believes are reasonable under the circumstances, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. These forward-looking statements include, among other things, the Exchange and senior secured lender approval of the Offering, the use of proceeds from the Offering, statements relating to Newtopia's business plans and outlook. Forward-looking statements are not a guarantee and are based on a number of estimates and assumptions management believes to be relevant and reasonable, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Certain of the "risk factors" that could cause actual results to differ materially from Newtopia's forward-looking statements in this press release include, without limitation: the termination of contracts by clients, risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; and other general economic, market and business conditions and factors, including the risk factors discussed or referred to in Newtopia's disclosure documents, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com including Newtopia's final long form prospectus dated March 30, 2020.
Should any factor affect Newtopia in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Last Trade: | C$0.005 |
Daily Volume: | 0 |
Market Cap: | C$866K |
November 27, 2024 September 24, 2024 September 17, 2024 August 08, 2024 May 23, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB